Mumbai (Thestates.news) | Pharma major, Zydus Lifesciences on Wednesday said that it has launched ANVIMO (Letermovir), a new and innovative treatment for the prevention of Cytomegalovirus (CMV) infection in Hematopoietic Stem Cell Transplantation (HSCT) and kidney transplant patients.
Sharvil Patel, MD of Zydus Lifesciences, said, “The introduction of ANVIMO marks a new era in bone marrow transplant and kidney transplant care in India. By making this critical therapy affordable and accessible, we are reinforcing our commitment to delivering world-class healthcare solutions. Our mission is to ensure that transplant patients get access to affordable, life-saving treatment.”
CMV infection remains one of the most serious complications in transplant patients, often leading to graft failure, decreased survival, and prolonged hospital stays.
Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone marrow suppression. Letermovir provides a safer, well-tolerated, and effective alternative, offering superior safety and reduced side effects while improving transplant outcomes.
With ANVIMO, Zydus Lifesciences is transforming CMV prophylaxis in India, ensuring that more transplant patients receive timely, effective, and affordable care, ultimately improving survival rates and quality of life, company release said. (UNI)
Zydus Life launches ANVIMO for HSCT, Kidney transplant treatment
